In a recent development, Aibotics Inc., a company listed on the OTC Bulletin Board, has filed a notice under SEC Rule 12b‑25, indicating a delay in the submission of its March 31, 2026, 10-Q report. The company, which trades in USD, cited the need for additional auditor review as the reason for this delay. The report is now expected to be filed within five calendar days following the original due date.
Aibotics Inc., with a market capitalization of approximately 567,695 USD, has seen its share price fluctuate over the past year. As of May 17, 2026, the close price stood at 0.001 USD, marking a significant drop from its 52-week high of 0.031 USD on May 22, 2025. The 52-week low was recorded at 0.0007 USD on May 17, 2026.
The company’s leadership, under the guidance of President and Chief Executive Officer Ben Kaplan, has assured stakeholders that no other required periodic reports were omitted and that there are no anticipated significant changes in operating results for the reported period. This assurance aims to maintain investor confidence amidst the delay.
Aibotics Inc. is known for its innovative approach in the biotechnology sector, focusing on developing therapies for neurological disorders. By leveraging a unique combination of plant-based compounds and advanced molecular biology techniques, the company aims to transform the lives of patients suffering from these conditions. Their mission is to provide novel, targeted treatments that can significantly improve the quality of life for those affected.
For further inquiries, stakeholders are encouraged to reach out using the contact information provided in the notice. As Aibotics Inc. navigates this period of additional review, the company remains committed to its mission and to delivering on its promise of innovative healthcare solutions.
